Journal Article

Neuroprotective effects of apigenin on retinal ganglion cells in ischemia/reperfusion: modulating mitochondrial dynamics in in vivo and in vitro models

zhang, Daowei, Wu, Jiawen, Li, Jufeng, Wu, Jihong, Li, Ting, Liu, Hongli, Zhang, Shenghai

2024

Overview

Background Retinal ischemia/reperfusion (RIR) is implicated in various forms of optic neuropathies, yet effective treatments are lacking. RIR leads to the death of retinal ganglion cells (RGCs) and subsequent vision loss, posing detrimental effects on both physical and mental health. Apigenin (API), derived from a wide range of sources, has been reported to exert protective effects against ischemia/reperfusion injuries in various organs, such as the brain, kidney, myocardium, and liver. In this study, we investigated the protective effect of API and its underlying mechanisms on RGC degeneration induced by retinal ischemia/reperfusion (RIR). Methods An in vivo model was induced by anterior chamber perfusion following intravitreal injection of API one day prior to the procedure. Meanwhile, an in vitro model was established through 1% oxygen and glucose deprivation. The neuroprotective effects of API were evaluated using H&E staining, spectral-domain optical coherence tomography (SD-OCT), Fluoro-Gold retrograde labeling, and Photopic negative response (PhNR). Furthermore, transmission electron microscopy (TEM) was employed to observe mitochondrial crista morphology and integrity. To elucidate the underlying mechanisms of API, the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, flow cytometry assay, western blot, cell counting kit-8 (CCK-8) assay, lactate dehydrogenase (LDH) assay, JC-1 kit assay, dichlorofluorescein-diacetate (DCFH-DA) assay, as well as TMRE and Mito-tracker staining were conducted. Results API treatment protected retinal inner plexiform layer (IPL) and ganglion cell complex (GCC), and improved the function of retinal ganglion cells (RGCs). Additionally, API reduced RGC apoptosis and decreased lactate dehydrogenase (LDH) release by upregulating Bcl-2 and Bcl-xL expression, while downregulating Bax and cleaved caspase-3 expression. Furthermore, API increased mitochondrial membrane potential (MMP) and decreased extracellular reactive oxygen species (ROS) production. These effects were achieved by enhancing mitochondrial function, restoring mitochondrial cristae morphology and integrity, and regulating the expression of OPA1, MFN2, and DRP1, thereby regulating mitochondrial dynamics involving fusion and fission. Conclusion API protects RGCs against RIR injury by modulating mitochondrial dynamics, promoting mitochondrial fusion and fission.

• Publisher: BioMed Central,BioMed Central Ltd,BMC
• Subject: Animals / Apigenin / Apigenin - pharmacology / Apigenin - therapeutic use / Apoptosis - drug effects / Biomedical and Life Sciences / Biomedicine / Cardiology / Care and treatment / Diagnosis / Dosage and administration / Ethylenediaminetetraacetic acid / Financial services industry / Ganglion / Indapamide / Male / Medicine/Public Health / Mental health / Mice, Inbred C57BL / Mitochondria - drug effects / Mitochondria - metabolism / Mitochondrial dynamics / Mitochondrial Dynamics - drug effects / Models, Biological / Neuroprotection / Neuroprotective agents / Neuroprotective Agents - pharmacology / Neuroprotective Agents - therapeutic use / Reactive Oxygen Species - metabolism / Reperfusion injury / Reperfusion Injury - drug therapy / Reperfusion Injury - pathology / Retina ischemia/reperfusion / Retinal ganglion cells / Retinal Ganglion Cells - drug effects / Retinal Ganglion Cells - metabolism / Retinal Ganglion Cells - pathology / Translational Ophthalmology